The Investigation of the Calcium Metabolism Changes in Rheumatic Mitral Valve Patients

Yıl 2022, Cilt: 25 Sayı: 1, 50 - 57, 18.04.2022

Aziz İnan Çelik Reşit Coşkun Muhammet Buğra Karaaslan Tahir Bezgin Süleyman Karakoyun Metin Çağdaş

Öz

Introduction: Rheumatic mitral valve disease (RMVD) is associated with autoimmune heart valve injury. Parathyroid hormone (PTH) and vitamin D are two essential molecules that have effects on the immune system. In this study, we aimed to evaluate the relationship between PTH and vitamin D in patients with RMVD.
Patients and Methods: We investigated 81 patients with RMVD and 75 healthy subjects. According to Wilkins score, baseline clinical, laboratory, and echocardiographic parameters were recorded, and all RMVD patients were analyzed. Multivariate logistic regression analysis was performed between the groups.
Results: Vitamin D levels were significantly low in the RMVD group. Patients were stratified according to Wilkins score [Wilkins score <7 (n= 50) vs. Wilkins score ≥7 (n= 31)]. Age, BMI, and PTH were significantly higher, and mitral valve area was significantly lower in Wilkins score ≥7 patients. In multivariate analysis, age (OR= 1.052; 95% CI 1.005-1.100, p= 0.028) and PTH (OR= 1.017; 95% CI 1.000-1.033, p= 0.047) were found to be independent predictors of high Wilkins score.

Conclusion: This study showed that vitamin D levels were low in patients with RMVD. According to the Wilkins score, PTH levels were significantly high in patients with a high Wilkins score. Changes in PTH and vitamin D levels may trigger inflammation and be responsible for valve damage.

Anahtar Kelimeler

Mitral valve, parathyroid hormone, vitamin D, inflammation

Kaynakça

• 1. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005;366(9480):155-68. [Crossref]
• 2. Vasan RS, Shrivastava S, Vijayakumar M, Narang R, Lister BC, Narula J. Echocardiographic evaluation of patients with acute rheumatic fever and rheumatic carditis. Circulation 1996;94:73-82. [Crossref]
• 3. Folger GM Jr, Hajar R, Robida A, Hajar HA. Occurrence of valvular heart disease in acute rheumatic fever without evidence carditis: color-flow Doppler identification. Br Heart J 1992;67:434-438. [Crossref]
• 4. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988;60(4):299-308. [Crossref]
• 5. Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol 2013;1:329-40. [Crossref]
• 6. Oztürk D, Ozcan Çelebi O, Ulusoy FV, Aydoğdu S. The relationship between serum parathormone levels and the severity of coronary artery disease. Turk Kardiyol Dern Ars 2012;40(7):589-94. [Crossref]
• 7. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003;89(5):552-72. [Crossref]
• 8. Yavuz B, Sen O, Deveci OS, Akin KO, Dal K, Ata N, et al. Serum 25-hydroxyvitamin D levels are correlated with mitral valve calcification score in patients with rheumatic mitral stenosis. J Heart Valve Dis 2012;21:570-5.
• 9. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006 Sep;92(1):39-48. [Crossref]
• 10. Schinke T, Karsenty G. Vascular calcification a passive process in need of inhibitors. Nephrol Dial Transplant 2000;15(9):1272-4. [Crossref]
• 11. Linhartová K, Veselka J, Sterbáková G, Racek J, Topolcan O, Cerbák R. Parathyroid Hormone and Vitamin D Levels Are Independently Associated With Calcific Aortic Stenosis. Circ J 2008;72(2):245-50. [Crossref]
• 12. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020;143(5):e229. [Crossref]
• 13. Froude J, Gibofsky A, Buskirk DR, Khanna A, Zabriskie JB. Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity. Curr Top Microbiol Immunol 1989;145:5-26. [Crossref]
• 14. Mukhopadhyay S, Varma S, Mohan Kumar HN, Yusaf J, Goyal M, Mehta V, et al. Circulating level of regulatory T cells in rheumatic heart disease: an observational study. Indian Heart J 2016;68(3):342-8. [Crossref]
• 15. Wen Y, Zeng Z, Gui C, Gui C, Li L, Li W. Changes in the expression of Th17 cellassociated cytokines in the development of rheumatic heart disease. Cardiovasc Pathol 2015;24(6):382-7. [Crossref]
• 16. Bas HD, Baser K, Yavuz E, Bolayir HA, Yaman B, Unlu S, et al. A shift in the balance of regulatory T and T helper 17 cells in rheumatic heart disease. J Invest Med 2014;62(1):78-83. [Crossref]
• 17. Kaden JJ, Kilic R, Sarikoc A, Hagl S, Lang S, Hoffmann U, et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. Int J Mol Med 2005;16(5):869-72. [Crossref]
• 18. Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000;102(21):2636-42. [Crossref]
• 19. Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients 2015;7(4):3011-21. [Crossref]
• 20. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1.25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000;374(2):334-8. [Crossref]
• 21. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and Autoimmunity: New Aetiological and Therapeutic Considerations. Ann Rheum Dis 2007;66(9):1137-42. [Crossref]
• 22. Korf H, Wenes M, Stijlemans B, Takiishi T, Robert S, Miani M, et al. 1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. Immunobiology 2012;217(12):1292-300. [Crossref]
• 23. Rigby WF, Yirinec B, Oldershaw RL, Fanger MW. Comparison of the effects of 1.25 dihydroxyvitamin D3 on T lymphocyte subpopulations. Eur J Immunol 1987;17(4):563-6. [Crossref]
• 24. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1.25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983;221(4616):1181-3. [Crossref]
• 25. Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, et al. 1.25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011;31(17):3653-69. [Crossref]
• 26. Overbergh L, Decallonne B, Waer M, Rutgeerts O, Valckx D, Casteels KM, et al. 1alpha.25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65. Diabetes 2000;49(8):1301-7. [Crossref]
• 27. Yusuf J, Jothinath P, Mukhopadhyay S, Vignesh V, Tyagi S. Evaluation of Serum 25-hydroxyvitamin D levels in calcific rheumatic mitral stenosis- a cross sectional study. Indian Heart J 2018;70(2):206-13. [Crossref]
• 28. Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol 2013;1:329-40. [Crossref]
• 29. Cheng SP, Liu CL, Liu TP, Hsu YC, Lee JJ. Association between parathyroid hormone levels and inflammatory markers among US adults. Mediators Inflamm 2014:709024. [Crossref]
• 30. Eren E, Ellidag HY, Cekin Y, Ayoglu RU, Sekercioglu AO, Yılmaz N. Heart valve disease: the role of calcidiol deficiency, elevated parathyroid hormone levels and oxidative stress in mitral and aortic valve insufficiency. Redox Rep 2014;19(1):34-9. [Crossref]